

Note

Copper Promoted Aerobic Oxidative C(sp³)-C(sp³) Bond Cleavage of N-(2-(Pyridin-2-yl)-ethyl)anilines

Yang Yu, Yong Zhang, Chengyu Sun, Lei Shi, Wei Wang, and Hao Li

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.9b02919 • Publication Date (Web): 15 Jan 2020

Downloaded from pubs.acs.org on January 15, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Copper Promoted Aerobic Oxidative C(sp³)-C(sp³) Bond Cleavage of *N*-(2-(Pyridin-2-yl)-ethyl)anilines


Yang Yu,[†] Yong Zhang,[†] Chengyu Sun,[†] Lei Shi,[§] Wei Wang^{†,‡,*} and Hao Li^{†,*}

[†]State Key Laboratory of Bioengineering Reactor, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China

[‡]Department of Pharmacology and Toxicology, and BIO5 Institute, University of Arizona, 1703 E. Mabel St., P. O. Box 210207, Tucson, AZ 85721-0207, USA

[§]Corporate R&D Division, Firmenich Aromatics (China) Co., Ltd., Shanghai, 201108, China


Supporting Information Placeholder




ABSTRACT: A strategy of aerobic oxidative C(sp³)-C(sp³) bond cleavage of *N*-ethylaniline derivatives bearing azaarenes for the synthesis of *N*-aryl formamides has been developed. This approach was carried out smoothly with the CuI/TEMPO/air system to give *N*-aryl formamides in yields of 50 to 90%. With this methodology, a mutagenically active compound was constructed in 90% yield. Moreover, the reaction also provided a “one-pot” synthetic tool for accessing a promoter of hematopoietic stem cells by difunctionalization in 61% yield.

1
2
3
4 C(sp³)-C(sp³) bond activation is gaining increasing attention in organic synthesis. Although many
5
6 examples of strained C(sp³)-C(sp³) bond activation have been reported,¹ the activation of unstrained
7
8 C(sp³)-C(sp³) bond is still a challenging subject due to the high bond-dissociation energy and lack of
9
10 selectivity.² Recently, several strategies to cleave inert C(sp³)-C(sp³) bonds have been developed:
11
12 β -elimination,³ oxidative cleavage,⁴ reductive scission,⁵ cross alkane metathesis⁶ and nucleophilic
13
14 substitution.⁷ Among them, the oxidative cleavage of C(sp³)-C(sp³) bonds adjacent to tertiary
15
16 aliphatic amines is of particular interest as the generated electrophilic iminium ions may serve as a
17
18 reactive intermediate to install a broad range of complex structures. For example, Wang reported
19
20 that Bu₄NI and TBHP promoted oxidative functionalization of tertiary amines to synthesize
21
22 methylene-bridged bis-1,3-dicarbonyl compounds.⁸ In addition, Opatz demonstrated the σ -bond
23
24 fragmentation of 1-benzyl-1,2,3,4-tetrahydroisoquinolines.⁹ Wang and co-workers realized the
25
26 C(sp³)-C(sp³) bond cleavage of 1,2-diamines by a photocatalytic system to obtain iminium ions and
27
28 C-radicals (Scheme 1, eq 1),¹⁰ and Sarpong developed a new approach for the cleavage of inert
29
30 C(sp³)-C(sp³) bond via silver-mediated ring-opening fluorination from *N*-acyl (Bz) unstrained cyclic
31
32 amines in 2018 (Scheme 1, eq 2).¹¹ Very recently, a copper-catalyzed selective cleavage of
33
34 C(sp³)-C(sp³) single bonds within amines using high pressure air has been developed by Beller's
35
36 group.¹² However, in contrast to tertiary aliphatic amines and *N*-Bz aliphatic secondary amines,
37
38 unprotected secondary aromatic amines are able to form stable *N,N*-diphenylhydrazines by a
39
40 dehydrogenative homocoupling reaction under oxidative conditions¹³ (we also found this
41
42 phenomenon in our study). Additionally, they can easily bind the transition metal catalysts and
43
44 inhibit catalytic cycles.¹⁴ The scission of unstrained C(sp³)-C(sp³) bonds in the presence of adjacent
45
46 secondary aromatic amines is unprecedented.

Scheme 1. The C(sp³)-C(sp³) bond cleavage strategies of amines.



Although the C(sp³)-C(sp) and C(sp³)-C(sp²) bond cleavage of unprotected secondary aromatic amine derivatives have been developed by Li and Wang respectively,¹⁵⁻¹⁶ the C(sp³)-C(sp³) bond cleavage of secondary aromatic amines has not been realized. Very recently, we introduced a copper-promoted intramolecular C-H oxidative amination reaction for the synthesis of aziridine derivatives.¹⁷ In this C-N bond formation reaction, a radical was proposed to form at the benzylic position of azaarenes followed by the annulation with secondary amines. In the continuation of our research concerning potential divergent synthetic methodologies and C-C bond functionalization,¹⁸ we questioned whether the substrates could be oxidized to enamine intermediates and then react with molecular oxygen to form 1,2-dioxetanes. Afterwards, C(sp³)-C(sp³) bond and O-O bond cleavage lead to *N*-aryl formamides, which have been widely employed in the preparation of bioactive compounds and fine chemical intermediates (Scheme 1, eq 3).¹⁹ Herein, we reported the cleavage of unstrained C(sp³)-C(sp³) bond adjacent to aromatic secondary amines to synthesize *N*-aryl formamides with air as the terminal oxidant under mild condition.

Table 1: Optimization of Reaction Conditions of C(sp³)-C(sp³) bond cleavage.^a


entry	copper	base	solvent	yield (%) ^b
1	CuI	DBU	dioxane	36
2	CuI	DBU	DMSO	N.R.
3	CuI	DBU	DMF	8
4	CuI	DBU	toluene	78
5	CuI	TBD	toluene	N.R.
6	CuI	DMAP	toluene	N.R.
7	CuI	DABCO	toluene	N.R.
8	Cu(OAc) ₂	DBU	toluene	21
9	CuBr	DBU	toluene	72
10 ^c	CuI	DBU	toluene	51
11 ^d	CuI	DBU	toluene	62
12 ^e	CuI	DBU	toluene	65
13 ^f	CuI	DBU	toluene	23

^a A solution of **1a** (0.2 mmol), copper salt (0.16 mmol) and TEMPO (0.4 mmol) with base (0.4 mmol) in the solvent stated (1.5 mL) was stirred for 2 h at 65 °C. ^b Isolated yield. ^c 0.1 mmol CuI was used. ^d 0.1 mmol TEMPO was used ^e Under O₂ atmosphere. ^f The reaction was carried out at rt.

In an initial attempt on the formation of *N*-aryl formamides, a solution of aniline **1a** (1.0 equiv) in the presence of CuI (0.8 equiv), DBU (2.0 equiv) and TEMPO (2.0 equiv) in dioxane was stirred for 2 h at 65 °C. The desired formamide product **2a** was obtained in 36% yield (Table 1, entry 1). Next, the reaction conditions were optimized to improve the reaction yield. The solvent screening revealed that polar aprotic solvent such as DMSO and DMF afforded the products in very poor yields (entries 2-3). In comparison, the nonpolar solvent toluene afforded a much higher yield (78%, entry 4). In addition to DBU, other organic bases such as 2,3,4,6,7,8-hexahydro-1*H*-pyrimido[1,2-*a*]pyrimidine (TBD), 1,4-diazabicyclo[2.2.2]octane (DABCO), and *N,N*-dimethylpyridin-4-amine (DMAP), were

also examined in toluene but only gave trace amount of products (entries 5-7). When screening different copper salts, Cu(OAc)₂ was found much less effective (21%, entry 8) and CuBr gave slightly lower yield than CuI (72%, entry 9). Lowering the loading of the copper salt or TEMPO also decreased the reaction yields (entries 10-11). Additionally, when the reaction was carried out under O₂ atmosphere, the desired product was obtained in 65% yield (entry 12). Notably, the yield was significantly lower at room temperature (23%, entry 13).

Scheme 2. Scope of CuI-promoted synthesis of *N*-aryl formamides via C(sp³)-C(sp³) cleavage.^a




^a Reaction conditions: a solution of **1** (0.2 mmol), CuI (0.16 mmol), DBU (0.4 mmol) and TEMPO (0.4 mmol) in toluene (1.5 mL) was stirred for 2 h at 65 °C. Isolated yield. ^b 6-(2-(Phenylamino)ethyl)nicotinonitrile **1u** was used as substrate.

1
2
3
4 With the optimal reaction conditions established, we then examined the substrate scope of
5
6 CuI-promoted C(sp³)-C(sp³) activation process for the formation of *N*-aromatic formamides **2**. As
7
8 shown in Scheme 2, almost all of the tested combinations produced the desired *N*-aromatic
9
10 formamides **2** with moderate to good isolated yields. The reaction has a high tolerance to
11
12 substituents on the para position of the phenyl ring: *para*-F, *para*-Cl, and *para*-Me only had a slight
13
14 impact on the yield (**2b-2c**, **2e**). Even aniline **1d** bearing a *para*-CF₃ group reacted smoothly to
15
16 afford *N*-aromatic formamide **2d** in 50% yield. Other anilines bearing various electron-donating
17
18 para-substituents on the phenyl ring were also suitable substrates for this protocol (**2f-2k**). Similarly,
19
20 we noted that the *meta*-substituted amines could also smoothly engage in this process to afford the
21
22 corresponding *N*-aromatic formamides **2l-2o** in moderate to good yields. A steric effect was seen in
23
24 substrates bearing *ortho*-substituents: *ortho*-Me and *ortho*-Ph afforded the corresponding products in
25
26 moderate yields (**2p-2q**). Furthermore, the aniline with two substituents of the phenyl ring gave
27
28 *N*-formylation product **2r** and **2s** in 77% and 65% yields respectively. The reaction was also very
29
30 effective for the construction of *N*-heterocyclic formamide **2t** in 73% yield. To further expand the
31
32 scope of the reaction, *N*-ethylaniline derivatives bearing functionalities different from *para*-nitro
33
34 azaarenes were investigated. By replacing NO₂ in **1a** with the slightly weaker electron-withdrawing
35
36 group CN (**1u**), the same product **2a** was obtained in 70% yield. When switching from **1a** to
37
38 *N*-(2-(3-nitropyridin-4-yl)ethyl)aniline (**1v**), the reaction still afforded the corresponding product **2a**
39
40 in acceptable yield (56%). However, when methyl 6-(2-(phenylamino)ethyl)nicotinate **1w** or
41
42 1-phenyl-3-(phenylamino)propan-1-one **1x** were used as the starting substrates, no bond cleavage
43
44 was observed. When *N*-methyl-*N*-(2-(5-nitropyridin-2-yl)ethyl)aniline **1y** was used as the starting
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

substrate under the standard reaction condition, no *N*-methyl-*N*-phenylformamide was detected at all.


This revealed that the proton of *N*-H is also essential in this reaction.

Scheme 3. The application of C(sp³)-C(sp³) bond cleavage process.




Formamide substructures are frequently encountered in many bioactive compounds. To test the applicability of our methodology, the mutagenically active molecule **2z** was synthesized by this C(sp³)-C(sp³) activation strategy.^{19b} The process proceeded readily with higher yield than any other reported method (90%). Furthermore, by unifying oxidative benzylic C-H carbonylation and C(sp³)-C(sp³) activation in one-pot, we successfully realized the difunctionalization of **1aa** to obtain fluorenone formamide **2aa** which has been used in maintaining and expanding of hematopoietic stem cells (HSC) in 61% yield (Scheme 3).^{19f} To test the practicality of this methodology, a gram-scale reaction using substrate **1a** was carried out to give product **2a** in 70% yield.

Scheme 4. Control experiments.



In order to understand the reaction mechanism, two control experiments were performed (Scheme 4). When 5.0 equiv of H₂O was added into the reaction system under air atmosphere, the reaction gave TEMPO addition product **3a** in 57% yield, and no desired *N*-phenylformamide **2a** was obtained. The addition of H₂O was thought to inhibit the formation of iminium intermediate. Additionally, without the addition of TEMPO, *N,N*-diphenylhydrazine **4u** was formed by using **1u** as the substrate in 15% yield, indicating a vital role of TEMPO as an additive in the transformation.

Scheme 5. The proposed mechanism for C(sp³)-C(sp³) bond cleavage.



Although the details of this C(sp³)-C(sp³) bond cleavage remains uncertain, a plausible mechanism is illustrated in Scheme 5. The iminium intermediate **I** is generated in the existence of copper salt and oxidant (TEMPO or O₂).¹⁶ With the strong electron withdrawing group NO₂, intermediate **I** is easily deprotonated to intermediate **II** by DBU. Enamine intermediate **III** is formed and reacts with oxygen to form 1,2-dioxetane intermediate **IV**. Finally, the fragmentation of **IV** sequentially underwent the C-C bond and O-O bond cleavage to furnish the desired product **2a**.²⁰ In addition, we

1
2
3
4 tried to identify the pyridine component by using commercially available 5-nitropicolinaldehyde (**5a**)
5
6 and 5-nitropicolinic acid (**6a**) as reference standards. Unfortunately, neither **5a** nor **6a** was stable
7
8 under the standard conditions. However, a mass peak corresponding to **5a** was detected in the study
9
10 of the reaction mixture (Supporting Information).
11
12

13
14 In summary, we have developed an efficient copper-promoted oxidative cleavage of C(sp³)-C(sp³)
15
16 bond adjacent to secondary aromatic amines providing *N*-aromatic formamides. A wide scope of
17
18 substituents on the aniline portion was tolerated to give the products in moderate to good yields.
19
20 Both TEMPO and oxygen played very important roles in this reaction. The methodology has been
21
22 successfully applied for the synthesis of a mutagenically active molecule in 90% yield and a HSC
23
24 active molecule in 61% yield, respectively. Further exploration of this organic transformation and
25
26 the application of this methodology in the synthesis of more biologically relevant molecules are
27
28 underway in our laboratories.
29
30
31
32
33

34 35 36 EXPERIMENT SECTION

37 38 39 **General Information**

40
41 Unless otherwise noted, all reagents were obtained commercially and used without further
42
43 purification. Unless otherwise specified, all other reagents were purchased from Acros, Aldrich,
44
45 Fisher, Adamas-beta Co. Ltd. or TCI and used without further purification. ¹H NMR spectra was
46
47 recorded at 400 MHz, ¹³C NMR spectra was recorded at 100 MHz. ¹H NMR spectra was recorded
48
49 with tetramethylsilane ($\delta = 0.00$ ppm) as internal reference; ¹³C NMR spectra was recorded with
50
51 CDCl₃ ($\delta = 77.00$ ppm) as internal reference. Chemical shifts were reported in parts per million
52
53 (ppm, δ) downfield from tetramethylsilane. Proton coupling patterns are described as singlet (s),
54
55 doublet (d), triplet (t), quartet (q), multiplet (m), and broad (br). Chromatography was carried out
56
57
58
59
60

1
2
3
4 with silica gel (200-300 mesh) using mixtures of petroleum ether (Bp 60-80 °C) and ethyl acetate as
5
6 eluents. Mass Spectra were obtained from the mass spectrometry facility of East China University of
7
8 Science and Technology.
9

10
11
12 **General procedure for the preparation of substrates:** To a solution of 5-nitro-2-vinylpyridine
13
14 (0.4 mmol, 120 mg) and aromatic amines **7** (0.8 mmol, 2 equiv) in toluene (2 mL) was added
15
16 Yb(OTf)₃ (0.02 mmol, 12.4 mg). The resulting solution was stirred for 2 h at 65 °C by oil bath. After
17
18 the reaction was completed, the reaction mixture was directly purified by column chromatography
19
20 (petroleum ether: ethyl acetate = 20:1~4:1) to give the corresponding product. Other Michael
21
22 addition product was prepared according to the literature.¹⁷
23
24
25
26
27

28 **4-(tert-Butyl)-N-(2-(5-nitropyridin-2-yl)ethyl)aniline(1f)**, yellowish solid, 87 mg (81%). Mp
29
30 84-86 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.31 (d, *J* = 2.4 Hz, 1H), 8.31 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz,
31
32 1H), 7.29 (d, *J* = 8.4 Hz, 1H), 7.14 (d, *J* = 8.8 Hz, 1H), 6.52 (d, *J* = 8.8 Hz, 1H), 3.53 (t, *J* = 6.0 Hz,
33
34 2H), 3.15 (t, *J* = 6.0 Hz, 2H), 1.20 (s, 9H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.8, 144.2,
35
36 143.8, 141.8, 139.6, 130.3, 125.1, 122.5, 111.7, 42.2, 36.8, 32.8, 30.5 ppm. HRMS (EI-TOF) *m/z*
37
38 calcd for C₁₇H₂₁N₃O₂: 299.1634, found 299.1630.
39
40
41
42
43

44 **4-Methoxy-N-(2-(5-nitropyridin-2-yl)ethyl)aniline(1g)**, yellowish solid, 94 mg (86%). Mp
45
46 69-71 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.39 (d, *J* = 2.4 Hz, 1H), 8.38 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz,
47
48 1H), 7.36 (d, *J* = 8.4 Hz, 1H), 6.79 (m, 2H), 6.61 (m, 2H), 3.75 (s, 3H), 3.57 (t, *J* = 6.0 Hz, 2H), 3.21
49
50 (t, *J* = 6.0 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 166.8, 152.4, 144.9, 142.8, 141.7,
51
52 131.4, 123.6, 115.0, 114.5, 55.8, 44.0, 37.7 ppm. HRMS (EI-TOF) *m/z* calcd for C₁₄H₁₅N₃O₃:
53
54 273.1113, found 273.1111.
55
56
57
58
59
60

***N*-(2-(5-Nitropyridin-2-yl)ethyl)-4-(trifluoromethoxy)aniline(1h)**, orange solid, 99 mg (76%).

Mp 101-103 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.39 (d, *J* = 2.8 Hz, 1H), 8.40 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.8 Hz, 1H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 1H), 6.59 (m, 2H), 4.19 (brs, 1 H), 3.60 (t, *J* = 6.0 Hz, 2H), 3.22 (t, *J* = 6.0 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 166.4, 146.5, 144.9, 142.9, 140.6, 131.5, 123.6, 122.5, 118.2 (*J*_{C-F} = 253.7 Hz), 113.2, 43.0, 37.4 ppm. HRMS (EI-TOF) *m/z* calcd for C₁₄H₁₂N₃O₃ F₃: 327.0831, found 327.0832.

***N*-(2-(5-Nitropyridin-2-yl)ethyl)-[1,1'-biphenyl]-4-amine(1i)**, yellow solid, 73 mg (57%). Mp

119-121 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.41 (d, *J* = 2.8 Hz, 1H), 8.40 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 1H), 7.53 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 2H), 7.44 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.0 Hz, 2H), 7.41-7.36 (m, 3H), 7.27 (m, 1H), 6.70 (m, 2H), 4.15 (brs, 1H), 3.67 (t, *J* = 7.2 Hz, 2H), 3.15 (t, *J* = 6.4 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 166.6, 147.0, 145.0, 142.9, 141.1, 131.5, 130.8, 128.7, 128.1, 126.3, 126.2, 123.6, 113.2, 42.6, 37.6 ppm. HRMS (EI-TOF) *m/z* calcd for C₁₉H₁₇N₃O₂: 319.1321, found 319.1322.

4-(Benzyloxy)-*N*-(2-(5-nitropyridin-2-yl)ethyl)aniline(1j), yellowish solid, 126 mg (80%). Mp

80-82 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.39 (d, *J* = 2.4 Hz, 1H), 8.30 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 1H), 7.42- 7.31 (m, 6H), 6.85 (d, *J* = 8.8 Hz, 1H), 6.59 (d, *J* = 8.8 Hz, 1H), 4.99 (s, 2H), 3.57 (t, *J* = 6.0 Hz, 2H), 3.13 (t, *J* = 6.0 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 166.8, 151.6, 144.9, 142.8, 142.0, 137.5, 131.4, 128.5, 127.8, 127.5, 123.6, 116.2, 114.3, 70.8, 43.9, 37.7 ppm. HRMS (EI-TOF) *m/z* calcd for C₂₀H₁₉N₃O₃: 349.1426, found 349.1424.

4-(Methylthio)-*N*-(2-(5-nitropyridin-2-yl)ethyl)aniline(1k), yellowish solid, 61 mg (53%). Mp

76-78 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.30 (d, *J* = 2.4 Hz, 1H), 8.29 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 1H), 7.26 (d, *J* = 8.4 Hz, 1H), 7.13 (m, 2H), 6.48 (m, 2H), 4.07 (brs, 1H), 3.50 (t, *J* = 6.0 Hz, 2H),

1
2
3
4 3.13 (t, $J = 6.0$ Hz, 2H), 2.32 (s, 3H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.5, 145.4, 143.8,
5
6 141.8, 130.4, 130.3, 123.7, 122.6, 112.5, 41.8, 36.4, 18.0 ppm. HRMS (EI-TOF) m/z calcd for
7
8 $\text{C}_{14}\text{H}_{15}\text{N}_3\text{O}_2\text{S}$: 289.0885, found 289.0883.

9
10
11 **2-Methyl-*N*-(2-(5-nitropyridin-2-yl)ethyl)aniline(1p)**, yellowish solid, 67 mg (65%). Mp 60-62
12
13 °C. ^1H NMR (400 MHz, CDCl_3): δ 9.30 (d, $J = 2.4$ Hz, 1H), 8.29 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz, 1H),
14
15 7.26 (d, $J = 8.4$ Hz, 1H), 7.05 (m, 1H), 6.96 (d, $J = 8.0$ Hz, 1H), 6.59 (m, 2H), 4.00 (brs, 1H), 3.55 (t,
16
17 $J = 6.4$ Hz, 2H), 3.18 (t, $J = 6.4$ Hz, 2H), 2.00 (s, 3H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ
18
19 165.8, 144.6, 143.7, 141.8, 130.4, 129.2, 126.1, 122.6, 122.5, 121.2, 116.2, 108.6, 41.8, 36.4, 16.4
20
21 ppm. HRMS (EI-TOF) m/z calcd for $\text{C}_{14}\text{H}_{15}\text{N}_3\text{O}_2$: 257.1164, found 257.1165.
22
23
24
25
26
27

28 ***N*-(2-(5-Nitropyridin-2-yl)ethyl)-[1,1'-biphenyl]-2-amine(1q)**, yellowish solid, 73 mg (57%).
29
30 Mp 126-128 °C. ^1H NMR (400 MHz, CDCl_3): δ 9.20 (d, $J = 2.8$ Hz, 1H), 8.32 (dd, $J_1 = 8.4$ Hz, $J_2 =$
31
32 2.8 Hz, 1H), 7.42-7.34 (m, 3H), 7.28-7.23 (m, 4H), 7.07 (dd, $J_1 = 7.6$ Hz, $J_2 = 1.6$ Hz, 1H), 6.80-6.76
33
34 (m, 2H), 3.61 (t, $J = 6.4$ Hz, 2H), 3.18 (t, $J = 6.4$ Hz, 2H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ
35
36 166.5, 144.7, 144.5, 142.7, 139.2, 131.3, 130.3, 129.4, 128.8, 128.7, 127.3, 123.5, 117.4, 110.6,
37
38 43.0, 37.3 ppm. HRMS (EI-TOF) m/z calcd for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_2$: 319.1321, found 319.1320.
39
40
41
42
43

44 **3,4-Dimethyl-*N*-(2-(5-nitropyridin-2-yl)ethyl)aniline(1r)**, orange solid, 77 mg (71%). Mp 61-63
45
46 °C. ^1H NMR (400 MHz, CDCl_3): δ 9.32 (s, 1H), 8.30 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz, 1H), 7.28 (d, $J =$
47
48 8.4 Hz, 1H), 6.87 (d, $J = 8.0$ Hz, 1H), 6.38 (m, 1H), 6.33 (dd, $J_1 = 8.0$ Hz, $J_2 = 2.8$ Hz, 1H), 3.52 (t, J
49
50 = 6.0 Hz, 2H), 3.13 (t, $J = 6.0$ Hz, 2H), 2.12 (s, 3H), 2.08 (s, 3H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz,
51
52 CDCl_3): δ 166.9, 145.7, 144.8, 137.5, 131.4, 130.3, 125.9, 123.6, 115.0, 110.5, 42.3, 37.8, 20.1, 18.7
53
54 ppm. HRMS (EI-TOF) m/z calcd for $\text{C}_{15}\text{H}_{17}\text{N}_3\text{O}_2$: 271.1321, found 271.1317.
55
56
57
58
59
60

1
2
3 ***N*-(2-(5-Nitropyridin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-1-amine(1s)**, yellow solid, 86
4
5
6 mg (72%). Mp 64-66 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.38 (d, *J* = 2.8 Hz, 1H), 8.38 (dd, *J*₁ = 8.4
7
8 Hz, *J*₂ = 2.4 Hz, 1H), 7.35 (d, *J* = 8.8 Hz, 1H), 7.03 (t, *J* = 8.0 Hz, 1H), 6.51 (m, 2H), 4.04 (brs, 1H),
9
10
11 3.61 (t, *J* = 6.4 Hz, 2H), 3.25 (t, *J* = 6.4 Hz, 2H), 2.72 (t, *J* = 6.4 Hz, 2H), 2.32 (t, *J* = 6.4 Hz, 2H),
12
13
14 1.84 (m, 2H), 1.72 (m, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 166.9, 145.3, 144.8, 142.9,
15
16
17 137.9, 131.5, 126.1, 123.6, 121.4, 118.6, 106.8, 42.9, 37.5, 30.1, 23.8, 23.1, 22.7 ppm. HRMS
18
19 (EI-TOF) *m/z* calcd for C₁₇H₁₉N₃O₂: 297.1477, found 297.1476.
20
21

22 ***N*-(2-(5-Nitropyridin-2-yl)ethyl)quinolin-6-amine(1t)**, yellow solid, 66 mg (56%). Mp 129-131
23
24 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.41 (d, *J* = 2.4 Hz, 1H), 8.62 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.2 Hz, 1H),
25
26
27 8.39 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 7.88 (d, *J* = 9.2 Hz, 1H), 7.38 (d, *J*
28
29 = 8.4 Hz, 1H), 7.29 (m, 1H), 7.08 (dd, *J*₁ = 9.2 Hz, *J*₂ = 2.8 Hz, 1H), 6.75 (d, *J* = 2.4 Hz, 1H), 3.73
30
31 (t, *J* = 6.4 Hz, 2H), 3.30 (t, *J* = 6.4 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 174.3, 166.4,
32
33
34 146.1, 145.6, 144.9, 143.0, 142.9, 134.0, 131.6, 130.1, 123.7, 121.5, 103.2, 103.1, 42.7, 37.1 ppm.
35
36
37 HRMS (EI-TOF) *m/z* calcd for C₁₆H₁₄N₄O₂: 294.1117, found 294.1118.
38
39
40
41

42 ***6*-(2-(Phenylamino)ethyl)nicotinonitrile(1u)**, orange solid, 63 mg (70%). Mp 72-74 °C. ¹H NMR
43
44 (400 MHz, CDCl₃): δ 8.83 (d, *J* = 1.6 Hz, 1H), 7.85 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, 1H), 7.17 (m, 1H),
45
46
47 6.71 (t, *J* = 1.6 Hz, 2H), 6.63 (m, 1H), 6.60 (m, 2H), 4.05 (br, 1H), 3.58 (t, *J* = 6.8 Hz, 2H), 3.16 (t, *J*
48
49 = 6.8 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 164.5, 152.2, 147.7, 139.5, 129.4, 123.5,
50
51
52 117.7, 116.8, 113.0, 107.7, 42.8, 37.8 ppm. HRMS (ESI-TOF) calcd for [M+H]⁺ C₁₄H₁₄N₃ :
53
54
55 224.1188, found 224.1189.
56
57
58
59
60

1
2
3
4 ***N*-(2-(5-Nitropyridin-2-yl)ethyl)-4-phenoxyaniline(1z)**, orange solid, 84 mg (63%). Mp 111-113
5
6 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.40 (d, *J* = 2.4 Hz, 1H), 8.40 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 1H),
7
8 7.38 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1H), 7.29 (m, 2H), 7.00 (t, *J* = 8.8 Hz, 1H), 6.91 (m, 4H), 6.63 (m,
9
10 2H), 4.00 (brs, 1H), 3.60 (t, *J* = 6.0 Hz, 2H), 3.24 (t, *J* = 6.0 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz,
11
12 CDCl₃): δ 166.6, 159.0, 148.0, 144.9, 144.2, 142.9, 131.5, 129.5, 123.6, 122.0, 121.3, 117.1, 114.0,
13
14 43.5, 37.6 ppm. HRMS (EI-TOF) *m/z* calcd for C₁₉H₁₇N₃O₃: 335.1270, found 335.1269.
15
16
17
18
19

20 ***N*-(2-(5-Nitropyridin-2-yl)ethyl)-9H-fluoren-2-amine(1aa)**, orange solid, 27 mg (20%). Mp
21
22 154-156 °C. ¹H NMR (400 MHz, CDCl₃): δ 9.34 (d, *J* = 2.8 Hz, 1H), 8.31 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.8
23
24 Hz, 1H), 7.53 (m, 2H), 7.38 (d, *J* = 7.6 Hz, 1H), 7.30 (d, *J* = 8.4 Hz, 1H), 7.23 (t, *J* = 7.6 Hz, 1H),
25
26 7.10 (m, 1H), 6.76 (m, 1H), 6.57 (dd, *J*₁ = 8.0 Hz, *J*₂ = 2.0 Hz, 1H), 3.74 (s, 2H), 3.61 (t, *J* = 6.4 Hz,
27
28 2H), 3.18 (t, *J* = 6.4 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.6, 146.1, 144.2, 143.9,
29
30 141.2, 141.1, 131.3, 130.4, 125.6, 123.9, 123.7, 122.6, 119.7, 117.5, 111.1, 110.1, 108.4, 42.2, 36.6,
31
32 35.9 ppm. HRMS (EI-TOF) *m/z* calcd for C₂₀H₁₇N₃O₂: 331.1321, found 331.1317.
33
34
35
36
37

38 **Typical procedure for synthesis of C(sp³)-C(sp³) bond cleavage product (2a as an example):**
39

40 A 10 mL round bottom flask was equipped with magnetic stir bar and cooling coil was charged with
41
42 *N*-(2-(5-nitropyridin-2-yl)ethyl)aniline (**1a**, 0.2 mmol, 49 mg), toluene (1.5 mL). Then, DBU (0.4
43
44 mmol, 60 μL), TEMPO (0.4 mmol, 62 mg) and CuI (0.16 mmol, 38 mg) were added to the solution.
45
46 The reaction mixture was exposed to the open air and was stirred for 2 h at 65 °C by oil bath. After
47
48 the reaction was completed, the reaction mixture was directly purified by column chromatography
49
50 [100 g silica gel was treated with 2 mL aqua ammonia (25% m/m)] with petroleum ether/CH₂Cl₂ =
51
52 1:1 to give C(sp³)-C(sp³) bond cleavage product **2a** in 78% yield.
53
54
55
56
57
58
59
60

1
2
3
4 **N-Phenylformamide(2a)**, yellow oil, 19 mg (78%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$): δ 10.2 (brs,
5
6 0.78H), 8.78 (d, $J = 11.2$ Hz, 0.22H), 8.27 (d, $J = 2.0$ Hz, 0.60H), 7.59 (d, $J = 7.6$ Hz, 1.22H), 7.32
7
8 (t, $J = 7.6$ Hz, 1.66H), 7.19 (d, $J = 7.6$ Hz, 0.44H), 7.07 (q, $J = 5.6$ Hz, 0.84H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR
9
10 (100 MHz, $\text{DMSO-}d_6$): δ 163.0, 160.1, 138.7, 138.6, 129.8, 129.3, 124.1, 124.0, 119.6, 118.0 ppm.
11
12
13
14 The spectroscopic data matched that previously reported^{20b}.

15
16
17 **N-(4-Fluorophenyl)formamide(2b)**, brown solid, 21 mg (75%). ^1H NMR (400 MHz, CDCl_3): δ
18
19 8.50 (d, $J = 11.2$ Hz, 0.40H), 8.29 (s, 0.58H), 7.74 (brs, 0.39H), 7.45 (m, 1.15H), 7.23 (m, 0.87H),
20
21 7.01-6.93 (m, 2.57H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 162.3, 159.4 (d, $J_{\text{C-F}} = 243.2$ Hz),
22
23 158.7, 158.5 (d, $J_{\text{C-F}} = 242.7$ Hz), 132.0, 131.8, 121.0, 120.0, 115.5 (d, $J_{\text{C-F}} = 22.8$ Hz), 114.6 (d, $J_{\text{C-F}}$
24
25 = 22.8 Hz) ppm. The spectroscopic data matched that previously reported^{21a}.

26
27
28
29
30 **N-(4-Chlorophenyl)formamide(2c)**, yellow solid, 25 mg (80%). ^1H NMR (400 MHz, CDCl_3): δ
31
32 8.58 (d, $J = 11.2$ Hz, 0.41H), 8.30 (s, 0.60H), 8.12 (brs, 0.37H), 7.43 (m, 1.23H), 7.34-7.27 (m,
33
34 0.42H), 7.25-7.21 (m, 0.92H), 7.21-7.19 (m, 0.75H), 6.97 (m, 0.80H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100
35
36 MHz, CDCl_3): δ 161.3, 157.9, 134.3, 134.2, 129.8, 129.7, 128.9, 128.1, 120.2, 119.1 ppm. The
37
38 spectroscopic data matched that previously reported^{21a}.

39
40
41
42
43 **N-(4-(Trifluoromethyl)phenyl)formamide(2d)**, brown solid, 19 mg (50%). ^1H NMR (400 MHz,
44
45 CDCl_3): δ 8.73 (m, 0.28H), 8.37 (brs, 0.61H), 7.62-7.51 (m, 2.59H), 7.19-7.12 (m, 0.55H) ppm.
46
47 $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 162.7, 159.7, 140.0, 139.9, 138.8, 126.3 (q, $J_{\text{C-F}} = 33.8$ Hz),
48
49 126.4, 124.1 (q, $J_{\text{C-F}} = 270.0$ Hz), 119.8, 117.9 ppm. The spectroscopic data matched that previously
50
51 reported^{21a}.

52
53
54
55
56
57 **N-p-Tolylformamide(2e)**, yellow solid, 22 mg (80%). ^1H NMR (400 MHz, CDCl_3): δ 8.62 (d, $J =$
58
59 11.6 Hz, 0.49H), 8.38 (s, 0.92H), 7.42 (d, $J = 8.0$ Hz, 0.39H), 7.15 (t, $J = 8.8$ Hz, 0.98H), 7.11 (m,
60

1
2
3
4 1.98H), 6.98 (d, $J = 8.0$ Hz, 1.09H), 2.33 (m, 3.00H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ
5
6 163.0, 159.1, 135.1, 134.5, 134.3, 134.1, 130.2, 129.5, 120.1, 119.1, 20.9, 20.8 ppm. The
7
8 spectroscopic data matched that previously reported^{21a}.

9
10
11 ***N*-(4-(*tert*-Butyl)phenyl)formamide(2f)**, yellow solid, 18 mg (51%). ^1H NMR (400 MHz,
12
13 CDCl_3): δ 8.58 (d, $J = 11.2$ Hz, 0.45H), 8.29 (s, 0.39H), 7.72 (br, 0.40H), 7.39 (d, $J = 8.8$ Hz,
14
15 0.82H), 7.29 (t, $J = 8.8$ Hz, 1.86H), 6.95 (d, $J = 8.4$ Hz, 0.94H), 1.24 (m, 9.00H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR
16
17 (100 MHz, CDCl_3): δ 161.8, 158.0, 147.5, 146.8, 133.2, 133.0, 125.6, 124.9, 118.8, 117.8, 33.4,
18
19 33.3, 30.3, 28.7 ppm. The spectroscopic data matched that previously reported^{21a}.

20
21
22 ***N*-(4-Methoxyphenyl)formamide(2g)**, yellow solid, 24 mg (79%). ^1H NMR (400 MHz, CDCl_3):
23
24 δ 8.43 (m, 0.46H), 8.26 (d, $J = 1.6$ Hz, 0.52H), 7.39 (brs, 0.47H), 7.38 (dd, $J_1 = 10.8$ Hz, $J_2 = 2.4$ Hz,
25
26 1.08H), 6.96 (dd, $J_1 = 6.4$ Hz, $J_2 = 2.4$ Hz, 1.01H), 8.84 (brs, 0.47H), 6.81-6.79 (m, 2.02H), 3.73 (m,
27
28 3H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 161.8, 157.7, 156.7, 155.7, 128.8, 128.4, 120.8,
29
30 120.7, 113.9, 113.3, 54.6, 54.4 ppm. The spectroscopic data matched that previously reported^{21a}.

31
32
33 ***N*-(4-(Trifluoromethoxy)phenyl)formamide(2h)**, yellow oil, 29 mg (71%). ^1H NMR (400 MHz,
34
35 CDCl_3): δ 8.61 (d, $J = 6.0$ Hz, 0.37H), 8.33 (s, 0.62H), 8.03 (brs, 0.32H), 7.52 (d, $J = 8.0$ Hz, 1.28H),
36
37 7.31 (s, 0.64H), 7.15 (m, 2.00H), 7.05 (m, 0.75H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 162.2,
38
39 158.9, 154.5, 152.9, 147.0 (q, $J_{\text{C-F}} = 113.1$ Hz), 145.7, 135.4, 135.3, 122.7, 121.9, 121.1, 119.1 (q,
40
41 $J_{\text{C-F}} = 253.3$ Hz) ppm. The spectroscopic data matched that previously reported^{21b}.

42
43
44 ***N*-([1,1'-Biphenyl]-4-yl)formamide (2i)**, yellow solid, 33 mg (83%). ^1H NMR (400 MHz,
45
46 CDCl_3): δ 8.65 (d, $J = 11.6$ Hz, 0.47H), 8.35 (d, $J = 2.0$ Hz, 0.53H), 7.56-7.49 (m, 5.50H), 7.39-7.35
47
48 (m, 2.06H), 7.30-7.26 (m, 1.11H), 7.08 (m, 1.45H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 161.2,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 157.8, 139.3, 139.0, 137.4, 136.8, 135.1, 134.8, 127.9, 127.7, 127.4, 126.7, 126.4, 126.2, 125.9,
5
6 125.8, 119.2, 118.1 ppm. The spectroscopic data matched that previously reported^{21b}.

7
8
9 ***N*-(4-(Benzyloxy)phenyl)formamide(2j)**, yellow solid, 28 mg (61%). ¹H NMR (400 MHz,
10 CDCl₃): δ 8.43 (d, *J* = 11.6 Hz, 0.44H), 8.21 (brs, 0.49H), 8.01 (d, *J* = 11.2 Hz, 0.40H), 7.37-7.24
11 (m, 6.74H), 6.95-6.83 (m, 3.01H), 4.96 (m, 2.00H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.2,
12 (m, 6.74H), 6.95-6.83 (m, 3.01H), 4.96 (m, 2.00H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.2,
13 158.9, 145.7, 135.4, 135.3, 122.7, 121.9, 121.1, 119.1 (q, *J*_{C-F} = 253.3 Hz) ppm. The spectroscopic
14 data matched that previously reported^{21c}.

15
16
17 ***N*-(4-(Methylthio)phenyl)formamide(2k)**, yellow oil, 28 mg (84%). ¹H NMR (400 MHz,
18 CDCl₃): δ 8.58 (d, *J* = 8.0 Hz, 0.44H), 8.27 (s, 0.87H), 7.40 (d, *J* = 8.4 Hz, 1.25H), 7.19-7.15 (m,
19 2.22H), 6.96 (d, *J* = 8.4 Hz, 0.91H), 2.40 (m, 3.00H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ
20 162.7, 159.4, 135.3, 134.5, 134.4, 134.2, 128.4, 127.9, 120.8, 119.7, 16.6, 16.5 ppm. The
21 spectroscopic data matched that previously reported^{21b}.

22
23
24 ***N*-(3-Fluorophenyl)formamide(2l)**, yellow oil, 19 mg(68%). ¹H NMR (400 MHz, CDCl₃): δ 8.63
25 (d, *J* = 11.2 Hz, 0.41H), 8.32 (brs, 0.58H), 7.58 (brs, 0.43H), 7.43 (m, 0.68H), 7.28-7.20 (m, 1.16H),
26 7.11 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.2 Hz, 0.70H), 6.85-6.72 (m, 1.63H) ppm. ¹³C{¹H} NMR (100 MHz,
27 CDCl₃): δ 163.3 (d, *J*_{C-F} = 245.6 Hz), 162.9 (d, *J*_{C-F} = 243.7 Hz), 162.8, 159.6, 138.5 (d, *J*_{C-F} = 10.1
28 Hz), 138.4 (d, *J*_{C-F} = 10.1 Hz), 131.2, 130.3, 115.3, 114.0, 112.1 (d, *J*_{C-F} = 21.0 Hz), 111.6 (d, *J*_{C-F} =
29 21.0 Hz), 107.7 (d, *J*_{C-F} = 26.1 Hz), 105.9 (d, *J*_{C-F} = 26.1 Hz) ppm. The compound was reported
30 previously^{20b}.

31
32
33 ***N*-(3-Chlorophenyl)formamide(2m)**, yellow solid, 20 mg (65%). ¹H NMR (400 MHz, CDCl₃): δ
34 8.68 (m, 0.43H), 8.39 (brs, 0.59H), 7.80 (m, 0.40H), 7.67 (t, *J* = 2.0 Hz, 0.67H), 7.38 (d, *J* = 8.4 Hz,
35 0.76H), 7.31-7.28 (m, 0.37H), 7.25 (m, 0.49H), 7.18-7.12 (m, 1.04H), 6.97 (d, *J* = 8.4 Hz, 0.42H)

1
2
3
4 ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 161.9, 158.8, 137.1, 137.0, 134.3, 133.5, 129.8, 129.1,
5
6 124.3, 123.8, 119.2, 117.7, 117.1, 115.6 ppm. The spectroscopic data matched that previously
7
8 reported^{21d}.

9
10
11 ***N*-(3-(Trifluoromethyl)phenyl)formamide(2n)**, brown solid, 18 mg (48%). ^1H NMR (400 MHz,
12
13 CDCl_3): δ 8.68 (d, $J = 11.2$ Hz, 0.37H), 8.49 (brs, 0.34H), 8.35 (s, 0.62H), 7.77 (s, 0.63H), 7.68 (m,
14
15 1.16H), 7.45-7.21 (m, 2.71H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 162.3, 159.2, 137.4, 132.3
16
17 (q, $J_{\text{C-F}} = 32.7$ Hz), 131.7, 131.3, 130.5, 129.7, 123.7 (q, $J_{\text{C-F}} = 270.8$ Hz), 123.5 (q, $J_{\text{C-F}} = 270.7$ Hz),
18
19 122.9, 121.9 (q, $J_{\text{C-F}} = 3.8$ Hz), 121.7, 121.4 (q, $J_{\text{C-F}} = 3.8$ Hz), 116.7 (q, $J_{\text{C-F}} = 3.8$ Hz), 115.4 (q, $J_{\text{C-F}}$
20
21 = 3.8 Hz) ppm. The spectroscopic data matched that previously reported^{21e}.

22
23
24
25
26
27 ***N*-m-Tolylformamide(2o)**, yellow oil, 19 mg (71%). ^1H NMR (400 MHz, CDCl_3): δ 8.68 (d, $J =$
28
29 11.6 Hz, 0.54H), 8.78 (d, $J = 1.2$ Hz, 0.48H), 7.70 (brs, 0.49H), 7.41 (m, 0.50H), 7.30 (m, 0.50H),
30
31 7.23 (m, 0.93H), 7.01 (brs, 0.34H), 6.96 (d, $J = 7.6$ Hz, 1.04H), 6.88 (m, 1.08H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR
32
33 (100 MHz, CDCl_3): δ 162.4, 158.8, 139.9, 139.2, 136.7, 136.5, 129.6, 129.0, 126.1, 125.7, 120.6,
34
35 119.6, 117.0, 115.9, 21.5, 21.4 ppm. The spectroscopic data matched that previously reported^{21b}.

36
37
38
39
40
41 ***N*-o-Tolylformamide(2p)**, brown solid, 15 mg (55%). ^1H NMR (400 MHz, CDCl_3): δ 8.48 (m,
42
43 0.62H), 8.37 (brs, 0.39H), 7.85 (d, $J = 8.0$ Hz, 0.39H), 7.16-7.01 (m, 3.80H), 2.23 (s, 3H) ppm.
44
45 $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 163.9, 159.6, 135.2, 134.7, 131.3, 130.6, 130.1, 129.1, 127.1,
46
47 126.7, 126.1, 125.6, 123.3, 120.9, 17.7, 17.6 ppm. The spectroscopic data matched that previously
48
49 reported^{21b}.

50
51
52
53
54 ***N*-([1,1'-Biphenyl]-2-yl)formamide(2q)**, yellow solid, 20 mg (50%). ^1H NMR (400 MHz,
55
56 CDCl_3): δ 8.62 (d, $J = 11.2$ Hz, 0.44H), 8.32 (d, $J = 7.6$ Hz, 0.52H), 8.23 (d, $J = 2.0$ Hz, 0.49H),
57
58 7.46-7.21 (m, 7.46H), 7.17-7.13 (m, 1.31H) ppm. $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 161.9, 158.9,
59
60

1
2
3
4 137.8, 137.3, 133.8, 133.7, 132.9, 131.9, 131.2, 130.2, 129.3, 129.2, 129.1, 128.8, 128.7, 128.2,
5
6 128.1, 125.3, 124.6, 121.4, 121.3, 118.1 ppm. The spectroscopic data matched that previously
7
8 reported^{21f}.

9
10
11 ***N*-(3,4-Dimethylphenyl)formamide(2r)**, yellow solid, 23 mg (77%). ¹H NMR (400 MHz,
12
13 CDCl₃): δ 8.62 (m, 0.49H), 8.33 (m, 0.45H), 8.23 (m, 0.45H), 7.43 (brs, 0.36H), 7.24 (m, 0.46H),
14
15 7.05 (m, 0.64H), 6.85 (m, 1.05H), 6.82 (t, *J* = 9.2 Hz, 1.14H), 2.23 (m, 6H) ppm. ¹³C{¹H} NMR
16
17 (100 MHz, CDCl₃): δ 162.9, 159.1, 138.2, 137.4, 134.6, 134.4, 133.8, 133.2, 130.7, 130.0, 121.4,
18
19 120.5, 117.5, 116.4, 19.9, 19.2, 19.1 ppm. The spectroscopic data matched that previously
20
21 reported^{21f}.

22
23
24
25
26
27 ***N*-(5,6,7,8-Tetrahydronaphthalen-1-yl)formamide(2s)**, brown solid, 23 mg (65%). ¹H NMR
28
29 (400 MHz, CDCl₃): δ 8.52 (d, *J* = 11.2 Hz, 0.66H), 8.43 (s, 0.28H), 7.89 (m, 0.63H), 7.30 (d, *J* = 7.6
30
31 Hz, 0.29H), 7.12 (m, 1.25H), 6.96 (m, 1.62H), 2.79 (m, 2H), 2.61 (m, 2H), 1.85 (d, *J* = 5.6 Hz, 2H),
32
33 1.77 (d, *J* = 5.6 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 163.4, 159.1, 139.2, 138.3,
34
35 134.8, 134.3, 128.8, 127.7, 127.1, 126.6, 126.1, 125.9, 120.5, 117.9, 29.8, 29.7, 24.6, 24.5, 22.8,
36
37 22.7, 22.5, 22.4 ppm. HRMS (EI-TOF) *m/z* calcd for C₁₁H₁₃NO:175.0997, found 175.0999. The
38
39 compound was reported previously^{21g}.

40
41
42
43
44
45
46 ***N*-(Quinolin-6-yl)formamide(2t)**, black solid, 25 mg (73%). ¹H NMR (400 MHz, CDCl₃): δ 9.48
47
48 (d, *J* = 11.2 Hz, 0.21H), 9.33 (s, 0.46H), 8.85-8.73 (m, 0.97H), 8.43 (s, 0.50H), 8.36 (d, *J* = 2.4 Hz,
49
50 0.51H), 8.00 (d, *J* = 8.4 Hz, 0.97H), 7.93 (d, *J* = 5.2 Hz, 0.52H), 7.56 (dd, *J*₁ = 9.2 Hz, *J*₂ = 2.4 Hz,
51
52 0.51H), 7.44 (m, 0.48H), 7.34 (m, 0.24H), 7.29 (q, *J* = 4.4 Hz, 0.51H) ppm. ¹³C{¹H} NMR (100
53
54 MHz, CDCl₃): δ 162.9, 159.8, 149.7, 149.4, 145.8, 145.4, 136.2, 135.6, 135.4, 135.3, 131.2, 129.9,
55
56
57
58
59
60

1
2
3
4 128.9, 123.3, 122.3, 122.2, 121.8, 116.8, 114.4 ppm. The spectroscopic data matched that previously
5
6 reported^{21h}.

7
8
9 ***N*-(4-Phenoxyphenyl)formamide(2z)**, yellow solid, 38 mg (90%). ¹H NMR (400 MHz, CDCl₃): δ
10
11 8.51 (d, *J* = 11.6 Hz, 0.44H), 8.29 (d, *J* = 1.6 Hz, 0.56H), 7.62 (brs, 0.41H), 7.43(m, 1.18H), 7.26
12
13 (m, 2.05H), 7.23 (brs, 0.51H), 7.07-6.91 (m, 5.96H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ
14
15 162.6, 158.8, 157.3, 157.1, 155.1, 154.0, 132.2, 131.8, 129.9, 129.8, 123.6, 123.3, 121.8, 121.3,
16
17 120.1, 119.6, 118.8, 118.6 ppm. The spectroscopic data matched that previously reported^{19b}.

18
19
20
21
22 ***N*-(9-oxo-9H-Fluoren-2-yl)formamide (2aa)**, brown solid, 27 mg (61%). ¹H NMR (400 MHz,
23
24 DMSO-*d*₆): δ 10.42 (s, 0.79H), 10.28 (d, *J* = 11.6 Hz, 0.21H), 8.85 (d, *J* = 11.2 Hz, 0.22H), 8.26 (m,
25
26 0.85H), 7.91 (d, *J* = 8.8 Hz, 0.21H), 7.86 (d, *J* = 1.6 Hz, 0.84H), 7.68-7.63 (m, 3.00H), 7.54-7.50 (m,
27
28 2.33H), 7.38-7.32 (m, 0.54H), 7.28-7.24 (m, 1.10H), 7.00 (m, 0.18H), 6.48 (m, 0.23H) ppm. ¹³C{¹H}
29
30 NMR (100 MHz, DMSO-*d*₆): δ 192.8, 192.7, 162.5, 160.0, 144.0, 139.7, 139.4, 139.3, 138.7, 138.6,
31
32 135.5, 135.4, 134.6, 134.0, 133.4, 133.2, 128.7, 128.6, 124.7, 124.0, 122.8, 122.2, 121.8, 120.7,
33
34 114.7, 112.8 ppm. HRMS (EI-TOF) *m/z* calcd for C₁₄H₉NO₂: 223.0633, found 223.0636. The
35
36 compound was reported previously^{19f}.

37
38
39
40
41
42
43 **Gram-scale reaction for the synthesis of 2a:** A 50 mL round bottom flask was equipped with
44
45 magnetic stir bar and cooling coil was charged with *N*-(2-(5-nitropyridin-2-yl)ethyl)aniline (**1a**, 3.5
46
47 mmol, 0.85 g), toluene (12 mL). Then, DBU (7 mmol, 1.05 mL), TEMPO (7 mmol, 1.05 g) and CuI
48
49 (2.8 mmol, 0.53 g) were added to the solution. The reaction mixture was exposed to the open air and
50
51 was stirred for 2 h at 65 °C by oil bath. After the reaction was completed, the reaction mixture was
52
53 directly purified by column chromatography [100 g silica gel was treated with 2 mL aqua ammonia
54
55
56
57
58
59
60

(25% m/m)] with petroleum ether/CH₂Cl₂ = 1:1 to give C(sp³)-C(sp³) bond cleavage product **2a** in 70% yield (0.27 g).

Synthesis of *N,N*-diphenylhydrazine **4u :** To a solution of 6-(2-(phenylamino)ethyl)nicotinonitrile (**1u**, 0.2 mmol, 44.6 mg) in toluene (1.5 mL) was added DBU (0.4 mmol, 60 μL) and CuI (0.16 mmol, 38 mg). The resulting solution was stirred for 2 h at 65 °C under air atmosphere by oil bath. After the reaction was completed, the reaction mixture was directly purified by column chromatography with petroleum ether/CH₂Cl₂ = 2:1 to give **4u** in 15% yield (6.8 mg).

6,6'-((1,2-Diphenylhydrazine-1,2-diyl)bis(ethane-2,1-diyl))dinicotinonitrile (4u**),** orange solid, Mp 167-169 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.70 (d, *J* = 2.0 Hz, 1H), 7.73 (dd, *J*₁ = 8.0 Hz, *J*₂ = 2.4 Hz, 1H), 7.15-7.09 (m, 3H), 6.77-6.69 (m, 3H), 3.84 (m, 2H), 3.16 (t, *J* = 7.6 Hz, 2H) ppm. ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 163.7, 152.2, 148.0, 139.6, 129.4, 123.6, 119.1, 116.8, 113.0, 107.7, 49.4, 36.7 ppm. HRMS (ESI-TOF) calcd for [M+Na]⁺ C₂₈H₂₄N₆Na : 467.1960, found 467.1961.

5-Nitropicolinaldehyde (5a**),** ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.09 (d, *J* = 0.8 Hz, 1H), 9.56 (s, 1H), 8.81 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.4 Hz, 1H), 7.17 (d, *J* = 8.4 Hz, 1H) ppm. ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆): δ 192.4, 155.7, 146.5, 145.8, 133.8, 122.9 ppm. The spectroscopic data matched that previously reported²².

5-Nitropicolinic acid (6a**),** ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.47 (bs, 1H), 8.76 (bs, 1H), 8.29 (bs, 1H) ppm. ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆): δ 165.23, 153.4, 146.1, 145.1, 133.5, 125.8 ppm. The spectroscopic data matched that previously reported²³.

ASSOCIATED CONTENT

Supporting Information

Experiment details and spectroscopic data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

wwang@pharmacy.arizona.edu; hli77@ecust.edu.cn

Author Contributions

All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENT

This work was supported by the National Natural Science Foundation of China (21572054, 21572055 and 21738002), the program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, the Fundamental Research Funds for the Central Universities and the China 111 Project (Grant B07023).

REFERENCES

- (1) (a) Kulinkovich, O. G. The Chemistry of Cyclopropanols. *Chem. Rev.* **2003**, *103*, 2597-2632. (b) Rubin, M.; Rubina, M.; Gevorgyan, V. Transition Metal Chemistry of Cyclopropenes and Cyclopropanes. *Chem. Rev.* **2007**, *107*, 3117-3179. (c) Carson, C. A.; Kerr, M. A. Heterocycles from Cyclopropanes: Applications in Natural Product Synthesis. *Chem. Soc. Rev.* **2009**, *38*, 3051-3060.
- (2) Some reviews on unstrained C-C bond activation, see: (a) Chen, F.; Wang, T.; Jiao, N. Recent Advances in Transition-Metal-Catalyzed Functionalization of Unstrained Carbon-Carbon Bonds. *Chem. Rev.* **2014**, *114*, 8613-8661. (b) Liang, Y.-F.; Jiao, N. Oxygenation via C-H/C-C Bond Activation with Molecular Oxygen. *Acc. Chem. Res.* **2017**, *50*,

1
2
3
4 1640-1653. (c) Sivaguru, P.; Wang, Z.; Zanoni, G.; Bi, X. Cleavage of Carbon-Carbon Bonds by Radical Reactions.

5
6
7 *Chem. Soc. Rev.* **2019**, *48*, 2615-2656.

8
9 (3) (a) Niwa, T.; Yorimitsu, H.; Oshima, K. Palladium-Catalyzed 2-Pyridylmethyl Transfer from 2-(2-Pyridyl)- ethanol
10
11 Derivatives to Organic Halides by Chelation-Assisted Cleavage of Unstrained Csp³-Csp³ Bonds. *Angew. Chem., Int. Ed.*

12
13 **2007**, *46*, 2643-2645. (b) Sai, M.; Yorimitsu, H.; Oshima, K. Allyl-, Allenyl-, and Propargyl- Transfer Reactions through
14
15 Cleavage of C-C Bonds Catalyzed by an *N*-Heterocyclic Carbene/Copper Complex: Synthesis of Multisubstituted
16
17 Pyrroles. *Angew. Chem., Int. Ed.* **2011**, *50*, 3294-3298.

18
19
20
21 (4) (a) Hernández-Guerra, D.; Rodríguez, M. S.; Suárez, E. Synthesis of Chiral β -Iodo- and
22
23 Vinylorganophosphorus(V) Compounds by Fragmentation of Carbohydrate Anomeric Alkoxy Radicals. *Org. Lett.* **2013**,

24
25 *15*, 250-253. (b) Liu, Z.-Q.; Zhao, L.; Shang, X.; Cui, Z. Unexpected Copper-Catalyzed Aerobic Oxidative Cleavage of
26
27 C(sp³)-C(sp³) Bond of Glycol Ethers. *Org. Lett.* **2012**, *14*, 3218-3221.

28
29
30
31 (5) Wilsily, A.; Nguyen, Y.; Fillion, E. Hydrogenolysis of Unstrained Carbon-Carbon σ Bonds: Stereoselective Entry
32
33 into Benzylic Tertiary Centers. *J. Am. Chem. Soc.* **2009**, *131*, 15606-15607.

34
35
36
37 (6) Jia, X.; Qin, C.; Friedberger, T.; Guan, Z.; Huang, Z. Efficient and Selective Degradation of Polyethylenes into
38
39 Liquid Fuels and Waxes under Mild Conditions. *Sci. Adv.* **2016**, *2*, e1501591.

40
41
42
43 (7) Li, H.; Li, W.; Liu, W.; He, Z.; Li, Z. An Efficient and General Iron-Catalyzed C-C Bond Activation with
44
45 1,3-Dicarbonyl Units as a Leaving Groups. *Angew. Chem., Int. Ed.* **2011**, *50*, 2975-2978.

46
47
48 (8) Xing, L.-J.; Wang, X.-M.; Li, H.-Y.; Zhou, W.; Kang, N.; Wang, P.; Wang, B. Metal-Free Synthesis of
49
50 Methylene-Bridged Bis-1,3-dicarbonyl Compounds via Oxidative C-C bond Cleavage of Tertiary Aliphatic Amines. *RSC*
51
52 *Adv.* **2014**, *4*, 26783-26786.

53
54
55
56 (9) Lipp, B.; Lipp, A.; Detert, H.; Opatz, T. Light-Induced Alkylation of (Hetero)aromatic Nitriles in a
57
58 Transition-Metal-Free C-C Bond Metathesis. *Org. Lett.* **2017**, *19*, 2054-2057.

- 1
2
3
4 (10) (a) Cai, S.; Zhao, X.; Wang, X.; Liu, Q.; Li, Z.; Wang, D.-Z. Visible-Light-Promoted C-C Bond Cleavage:
5
6 Photocatalytic Generation of Iminium Ions and Amino Radicals. *Angew. Chem., Int. Ed.* **2012**, *51*, 8050-8053. (b) Zhao,
7
8 Y.; Cai, S.; Li, J.; Wang, D.-Z. Visible-Light Photo-Catalytic C-C Bond Cleavages: Preparations of
9
10 *N,N*-Dialkylformamides from 1,2-Vicinal Diamines. *Tetrahedron* **2013**, *69*, 8129-8131.
11
12
13
14 (11) Roque, J. B.; Kuroda, Y.; Göttemann, L. T.; Sarpong, R. Deconstructive Fluorination of Cyclic Amines by
15
16 Carbon-Carbon Cleavage. *Science* **2018**, *361*, 171-174.
17
18
19 (12) Li, W.; Liu, W.; Leonard, D. K.; Rabeah, J.; Junge, K.; Brückner, A.; Beller, M. Practical Catalytic Cleavage of
20
21 $C(sp^3)$ - $C(sp^3)$ Bonds in Amines. *Angew. Chem., Int. Ed.* **2019**, *58*, 10693-10697.
22
23
24 (13) Yan, X.-M.; Chen, Z.-M.; Yang, F.; Huang, Z.-Z. A Dehydrogenative Homocoupling Reaction for the Direct
25
26 Synthesis of Hydrazines from *N*-Alkylanilines in Air. *Synlett*, **2011**, 569.
27
28
29 (14) (a) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. Recent Advances in the Transition Metal-Catalyzed Twofold
30
31 Oxidative C-H Bond Activation Strategy for C-C and C-N Bond Formation. *Chem. Soc. Rev.* **2011**, *40*, 5068-5083. (b)
32
33 Allen, S. E.; Walvoord, R. R.; Padilla-Salinas, R.; Kozlowski, M. C. Aerobic Copper-Catalyzed Organic Reactions.
34
35 *Chem. Rev.* **2013**, *113*, 6234-6458. (c) Liu, J.; Li, H.; Spannenberg, A.; Franke, R.; Jackstell, R.; Beller, M. Selective
36
37 Palladium-Catalyzed Aminocarbonylation of Olefins to Branched Amides. *Angew. Chem., Int. Ed.* **2016**, *55*,
38
39 13544-13548. (d) Guo, S.; Qian, B.; Xie, Y.; Xia, C.; Huang, H. Copper-Catalyzed Oxidative Amination of Benzoxazoles
40
41 via C-H and C-N Bond Activation: A New Strategy for Using Tertiary Amines as Nitrogen Group Sources. *Org. Lett.*
42
43 **2011**, *13*, 522-525. (e) Zhou, W.; Fan, W.; Jiang, Q.; Liang, Y.-F.; Jiao, N. Copper-Catalyzed Aerobic Oxidative C-C
44
45 Bond Cleavage of Unstrained Ketones with Air and Amines. *Org. Lett.* **2015**, *17*, 2542-2545.
46
47
48 (15) Song, R.-J.; Liu, Y.; Hu, R.-X.; Liu, Y.-Y.; Wu, J.-C.; Yang, X.-H.; Li, J.-H. Oxidative Cleavage of the
49
50 Carbon-Carbon σ -Bond Using Reusable Copper on Iron. *Adv. Synth. Catal.* **2011**, *353*, 1467-1473.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 (16) Yang, S.; Li, P.; Wang, Z.; Wang, L. Photoinduced Oxidative Formylation of *N,N*-Dimethylanilines with
5
6
7 Molecular Oxygen without External Photocatalyst. *Org. Lett.* **2017**, *19*, 3386-3389.

8
9 (17) Yu, Y.; Li, M.; Zhang, Y.; Liu, Y.; Shi, L.; Wang, W.; Li, H. Construction of *N*-Alkyl- and *N*-Arylaziridines from
10
11
12 Unprotected Amines via C-H Oxidative Amination Strategy. *Org. Lett.* **2019**, *21*, 904-907.

13
14 (18) (a) Xu, L.; Li, H.; Liao, Z.; Lou, K.; Xie, H.; Li, H.; Wang, W. Divergent Synthesis of Imidazoles and
15
16
17 Quinolines via Pd(OAc)₂-Catalyzed Annulation of *N*-Allylamidines. *Org. Lett.* **2015**, *17*, 3434-3437. (b) Huang, H.;
18
19
20 Zhang, X.; Yu, C.; Li, X.; Zhang, Y.; Wang, W. Highly Regio- and Stereoselective Synthesis of *Z* and *E* Enol Esters by
21
22
23 an Amine Catalyzed Conjugate Addition-rearrangement Reaction of Ynals with Carboxylic Acids. *ACS. Catal.* **2016**, *6*,
24
25
26 8030-8035. (c) Tong, M.; Zhang Y.; Qin C.; Fu, Y.; Liu, Y.; Li, H.; Wang, W. Alkenylazaarenes as Dipolarophiles in
27
28
29 1,3-Dipolar Cycloaddition of Nitrones: Regioselectivity-Switchable and Highly Diastereoselective Synthesis of
30
31
32 Multisubstituted Isoxazolidines. *Org. Chem. Front.* **2018**, *5*, 2945-2949. (d) Wang, H.; Yang, W.; Liu, H.; Wang, W.; Li,
33
34
35 H. FeCl₃ Promoted Highly Regioselective [3+2] Cycloaddition of Dimethyl 2-Vinyl and Aryl
36
37
38 Cyclopropane-1,1-dicarboxylates with Aryl Isothiocyanates. *Org. Biomol. Chem.* **2012**, *10*, 5032-5035. (e) Wang, S.; Yu,
39
40
41 Y.; Chen, X.; Zhu, H.; Du, P.; Liu, G.; Lou, L.; Li, H.; Wang, W. FeCl₃-Catalyzed Selective Acylation of Amines with
42
43
44 1,3-Diketones via C-C Bond Cleavage. *Tetrahedron Lett.* **2015**, *56*, 3093-3096.

45
46 (19) (a) Popoff, I. C.; Singhal, G. H.; Engle, A. R. Antimalarial Agents. 7. Compounds Related to
47
48
49 4,4'-Bis(aminophenyl) Sulfone. *J. Med. Chem.* **1971**, *14*, 550-551. (b) Yuta, K.; Jurs, P. C. Computer-Assisted
50
51
52 Structure-Activity Studies of Chemical Carcinogens. Aromatic Amines. *J. Med. Chem.* **1981**, *24*, 241-251. (c) Klapars,
53
54
55 A.; Huang, X.; Buchwald, S. L. A General and Efficient Copper Catalyst for the Amidation of Aryl Halides. *J. Am.*
56
57
58 *Chem. Soc.* **2002**, *124*, 7421-7428. (d) Porcheddu, A.; Giacomelli, G.; Salaris, M. Microwave-Assisted Synthesis of
59
60
61 Isonitriles: A General Simple Methodology. *J. Org. Chem.* **2005**, *70*, 2361-2363. (e) Reddy, N. V.; Prasad, K. R.; Reddy,
62
63
64 P. S.; Kantam, M. L.; Reddy, K. R. Metal Free Oxidative Coupling of Aryl Formamides with Alcohols for the Synthesis

1
2
3
4 of Carbamates. *Org. Biomol. Chem.* **2014**, *12*, 2172-2175. (f) Cotari, J.; Wang, Z. Compositions and Methods of Making
5
6 Expanded Hematopoietic Stem Cells Using Derivatives of Fluorene. WO Patent 084452 A1, 2019.
7

8
9 (20) (a) Blue, K.; Kapst, U.; Voerckel, C. Studies on the Oxidation of Enamines with Molecular Oxygen 2. Oxidation
10
11 of 1 -Amino But-1-enes. *J. Prakt. Chem.* **1989**, *331*, 671-676. (b) Zhang, C.; Xu, Z.; Shen, T.; Wu, G.; Zhang, L.; Jiao, N.
12
13 Mn-promoted Aerobic Oxidative C-C Bond Cleavage of Aldehydes with Dioxygen Activation: A Simple Synthetic
14
15 Approach to Formamides. *Org. Lett.* **2012**, *14*, 2362-2365. (c) Sun, H.; Yang, C.; Gao, F.; Li, Z.; Xia, W. Oxidative C-C
16
17 Bond Cleavage of Aldehydes via Visible-Light Photoredox Catalysis. *Org. Lett.* **2013**, *15*, 624-627.
18
19

20
21 (21) (a) Li, X. -F.; Zhang, X. G.; Chen, F.; Zhang, X.-H. Copper-Catalyzed *N*-Formylation of Amines through Tandem
22
23 Amination/Hydrolysis/Decarboxylation Reaction of Ethyl Bromodifluoroacetate. *J. Org. Chem.* **2018**, *83*, 12815-12821.
24
25 (b) Yin, J.; Zhang, J.; Cai, C.; Deng, G.-J.; Gong, H. Catalyst-Free Transamidation of Aromatic Amines with Formamide
26
27 Derivatives and Tertiary Amides with Aliphatic Amines. *Org. Lett.* **2019**, *21*, 387-392. (c) Kobayashi, G.; Saito, T.;
28
29 Kitano, Y. A Novel Method for Preparing Isocyanides from *N*-Substituted Formamides with Chlorophosphate
30
31 Compounds. *Synthesis* **2011**, 3225-3234. (d) Hosseine-Sarvari, M.; Sharghi, H. ZnO as a New Catalyst for *N*-Formylation
32
33 of Amines in Solvent-Free Conditions. *J. Org. Chem.* **2006**, *71*, 6652-6654. (e) Tan, E.; Ung, S.; Corbet, M.
34
35 Microwave-Assisted Formylations of Weakly Basic Anilines with Methyl Formate Catalyzed by Calcium and Hydrogen
36
37 Triflimides. *Eur. J. Org. Chem.* **2016**, 1836-1840. (f) Mutra, M. R.; Dhandabani, G. K.; Wang, J.-J. Mild Access to
38
39 *N*-Formylation of Primary Amines using Ethers as C1 Synthons under Metal-Free Conditions. *Adv. Synth. Catal.* **2018**,
40
41 *360*, 3960-3968. (g) Uhle, F. C.; Vernick, C. G.; Schmir, G. L. The Synthesis of 1,3,4,5-Tetrahydrobenz [cd] indole. *J.*
42
43 *Am. Chem. Soc.* **1955**, *77*, 3334-3337. (h) Dong, X.; Wang, Z.; Duan, Y.; Yang, Y. One-pot Selective *N*-Formylation of
44
45 Nitroarenes to Formamides Catalyzed by Core-shell Structured Cobalt Nanoparticles. *Chem. Commun.* **2018**, *54*,
46
47 8913-8916.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(22) Hood, J.; KC, S. K. Indazole-3-carboxamides and Their Use as Wnt/B-catenin Signaling Pathway Inhibitors. WO Patent 040215 A1, 2013.

(23) Muller, G. W.; Chen, R. S. C.; Rucheiman, A. L. 5-Substituted Isoindoline Compounds. WO Patent 027542 A2, 2018.